OncoMatch/Clinical Trials/NCT06196294
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Is NCT06196294 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Cell therapy for solid tumors for pancreas cancer.
Treatment: Cell therapy for solid tumors — The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Mesothelioma
Tumor Agnostic
Biomarker criteria
Required: GPC3 overexpression
cancer that expresses GPC3 or Mesothelin protein
Required: MSLN overexpression
cancer that expresses GPC3 or Mesothelin protein
Prior therapy
Cannot have received: gene therapy
Lab requirements
Blood counts
adequate blood function
Kidney function
adequate kidney function
Liver function
adequate liver function
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify